Specialized Anti-Mycobacterial Solutions for High-Security and Extreme Environments
Legal Citation
Summary of the Inventive Concept
This inventive concept adapts the original anti-mycobacterial drug concept for specific, narrow markets and unique operational environments, addressing the need for effective treatments in high-security settings, disaster relief situations, and extreme weather conditions.
Background and Problem Solved
The original anti-mycobacterial drug concept, while effective, has limitations in terms of its applicability in high-security environments, disaster relief situations, and extreme weather conditions. This new inventive concept addresses these limitations by providing specialized solutions tailored to these specific contexts.
Detailed Description of the Inventive Concept
The inventive concept comprises a series of oligo(carbamoylated guanidine) (OCG) structures, wherein n is an integer ranging from 3 to 50, X is an alkylene, and Y is a linear or cyclic alkylene. These OCGs are designed to be effective against mycobacterial infections in high-security environments, disaster relief situations, and extreme weather conditions. The inventive concept also includes pharmaceutical compositions, methods of treatment, and systems for delivering these OCGs in these specialized contexts.
Novelty and Inventive Step
The novelty of this inventive concept lies in its adaptation of the original anti-mycobacterial drug concept for specific, narrow markets and unique operational environments. The inventive step is the recognition of the need for specialized solutions in these contexts and the development of OCG structures and delivery systems tailored to these needs.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include varying the structure of the OCGs, using different alkylene or arylene groups, or incorporating additional functional groups to enhance efficacy or stability. Variations could also include different delivery systems, such as topical compositions or injectable formulations, to suit specific operational environments.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of high-security environments, disaster relief, and extreme weather conditions. Target markets could include government agencies, humanitarian organizations, and private companies operating in these specialized contexts.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/17 |
| A | A61 | A61K31/133 |
| A | A61 | A61K31/277 |
| A | A61 | A61K31/4409 |
| A | A61 | A61K31/47 |
| A | A61 | A61K31/496 |
| A | A61 | A61K31/498 |
| A | A61 | A61K31/4965 |
| A | A61 | A61K31/5377 |
| A | A61 | A61P31/06 |
| C | C07 | C07C279/12 |
| C | C07 | C07D295/215 |
| C | C08 | C08G65/00 |
| C | C08 | C08G71/02 |
| C | C07 | C07C2601/16 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, specifically anti-mycobacterial drug development, involving organic synthesis, medicinal chemistry, and drug design for infectious disease treatment
Person of Ordinary Skill (PHOSITA) Profile
A researcher with a PhD in pharmaceutical chemistry or organic synthesis, experienced in drug design, structure-activity relationships, and modification of therapeutic compounds, familiar with synthetic organic chemistry techniques and mycobacterial infection treatment strategies
Obviousness Rationale
A PHOSITA would recognize that the PTD's specialized environmental adaptations represent predictable variations of the source patent's core oligo(carbamoylated guanidine) structure. The modifications involve routine design choices in drug delivery and formulation that would be obvious to a skilled practitioner seeking to optimize anti-mycobacterial treatments for specific operational contexts. The fundamental molecular structure remains substantially unchanged, with variations primarily addressing implementation and delivery strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,521 |
|---|---|
| Title | Anti-mycobacterial drugs |
| Assignee(s) | The Florida International University Board of Trustees |